Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Botensilimab · AGEN-1181

Monoclonal antibody · Antagonist of CTLA-4 · developed by Agenus

Phase 2/3 Most advanced trial

AGEN Developer

2 Registered trials

What is Botensilimab?

Botensilimab is an Fc-engineered recombinant human IgG1 monoclonal antibody that binds CTLA-4 on T cells and blocks its inhibitory signaling, enhancing cytotoxic T-lymphocyte-mediated immune responses against cancer. It is studied in resectable solid tumors with and without mismatch repair deficiency and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AGEN-1181
Drug type: Monoclonal antibody
Targets: CTLA-4
Mechanism: Antagonist of CTLA-4
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Agenus Inc. (AGEN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: 1Z5YC3ME5N

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06279130	Phase 2/3	Resectable MMR-deficient Solid Tumors	Recruiting	AGEN
NCT06322108	Phase 2	Non-small Cell Lung Cancer	Active not recruiting	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-small Cell Lung CancerResectable MMR-deficient Solid TumorsResectable MMR-proficient Solid Tumors

Other drugs acting on CTLA4

Ipilimumab FDA approved Tremelimumab FDA approved Cadonilimab Early Phase 1 Firastotug Phase 1 Muzastotug Phase 2 Pembrolizumab/Quavonlimab Phase 1/2 Volrustomig Phase 3 Zalifrelimab Phase 1/2

More from Agenus

AGEN1223 Phase 1 AGEN1571 Phase 1 AGEN2017 Phase 1 AGEN2373 Phase 1/2 Balstilimab Phase 2/3 BMS-986442 Phase 1 QS21 Phase 2 Vitespen Phase 2 Zalifrelimab Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.

Follow AGEN, the company behind Botensilimab

See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGEN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z